Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,424 across all filing types
Latest filing 2024-09-26 Call Transcript
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
Intimation of Conference Call
Call Transcript Classification · 95% confidence The document is a notification about an upcoming conference call scheduled for October 1, 2024, where company officials will discuss a proposed strategic merger. It includes dial-in details and speaker information but does not contain any financial data, analysis, or detailed report content. The document is short (2252 characters) and serves as an announcement of the call rather than the transcript or report itself. Therefore, it fits the category of a Call Transcript announcement or invitation. Since it is an announcement of a conference call, the appropriate classification is Call Transcript (CT).
2024-09-26 English
Amalgamation/Merger
M&A Activity Classification · 95% confidence The document is a detailed announcement from SeQuent Scientific Limited regarding the approval by its Board of Directors of a composite scheme of amalgamation (merger) involving Viyash Life Sciences Private Limited and its group companies, and Sequent Research Limited, a wholly owned subsidiary of Sequent. It includes specifics about the merger scheme, share exchange ratios, changes in shareholding patterns, rationale for the merger, and regulatory approvals required. The document references compliance with SEBI regulations and includes annexures detailing entities involved, financial sizes, and business rationale. It also contains a joint press release about the strategic merger. The content is focused on merger activity, regulatory disclosures related to the merger, and detailed merger terms rather than financial results, governance changes, or other report types. Therefore, the document fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2024-09-26 English
Scheme of arrangement
M&A Activity Classification · 95% confidence The document is a detailed announcement from SeQuent Scientific Limited regarding the approval by its Board of Directors of a composite scheme of amalgamation (merger) involving Viyash Life Sciences Private Limited and its group companies, and Sequent Research Limited, a wholly owned subsidiary of Sequent. It includes specifics about the merger scheme, regulatory approvals required, share exchange ratios, changes in shareholding patterns, and rationale for the merger. The document references compliance with SEBI regulations and includes annexures detailing entities involved, financial sizes, and strategic rationale. It also contains a joint press release about the strategic merger. The content is focused on merger activity, regulatory compliance disclosures, and shareholder impact related to the merger. This fits the definition of a filing related to M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids. The document is not a full merger proxy statement or tender offer filing (which would be MA), but an announcement and disclosure under regulatory requirements about the merger scheme. Therefore, the appropriate classification is M&A Activity (TAR). The document length and detail support a high confidence score.
2024-09-26 English
Closure of Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice regarding the closure of the trading window for insiders ahead of the announcement of unaudited financial results for the quarter and half year ending September 30, 2024. It references the upcoming financial results but does not contain any financial data or the results themselves. The document is short (1783 characters) and serves as an announcement related to compliance with insider trading regulations. It is not a financial report, earnings release, or any detailed report but rather a regulatory announcement informing stock exchanges and the public about the trading window closure period. Therefore, it fits best under Regulatory Filings (RNS).
2024-09-26 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice regarding the closure of the trading window for insiders ahead of the announcement of unaudited financial results for the quarter and half year ending September 30, 2024. It does not contain any financial data or results itself, nor does it present a report. It is an announcement related to compliance with insider trading regulations and the timing of financial results disclosure. The document length is short (1783 characters), and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-26 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a detailed summary of the proceedings of the Thirty-Ninth Annual General Meeting (AGM) of Sequent Scientific Limited held on September 17, 2024. It includes information about the meeting attendees, the agenda items discussed, voting procedures, and the conclusion of the meeting. The document is not the full Annual Report or financial statements but rather a formal record of the AGM proceedings. It also mentions the delay in submission of these proceedings and is addressed to stock exchanges as per regulatory requirements. This matches the definition of 'AGM Information' which covers presentations and materials shared during the AGM. The document length (9405 characters) and content confirm it is not a brief announcement or a report publication notice but the actual AGM proceedings summary.
2024-09-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.